Nadege C.
- Country
- France
- Department
- institut d'hematologie et d'oncologie pediatrique
Research Overview
- Phase 1b/2 Study of Ifinatamab Deruxtecan in Pediatric Patients with Relapsed or Refractory Solid Tumors (Neuroblastoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma)
- Randomized Phase II/III Study of Cabozantinib Maintenance Versus Best Supportive Care in Osteosarcoma Patients After First‑Line Chemotherapy (FOSTER‑CabOS)
- Phase II Evaluation of RO7435846 in Combination with Multiple Agents for Biomarker-Positive Advanced or Metastatic Solid Tumors
Data & Insights
Has run more than one trial at 97 of 213 partner sites.
Specializations
Pediatric Oncology Focus
This investigator specializes in treating pediatric and adolescent cancers with particular emphasis on solid tumors and sarcomas. Their research encompasses both early-phase and advanced therapeutic approaches for young patients.
- Rhabdomyosarcoma
- Ewing Sarcoma
- Osteosarcoma
- CNS Tumors
Targeted Therapies
The investigator focuses on developing innovative therapeutic combinations utilizing targeted agents and immunotherapies for pediatric cancers. Their work includes studies of molecular-based treatments for specific genetic alterations.
- MEK Inhibitors
- PD-L1 Inhibitors
- Tyrosine Kinase Inhibitors
- NTRK Fusion Targeting
Advanced Disease Management
Expertise in treating refractory and relapsed cancers in pediatric populations, with particular focus on developing maintenance therapy strategies and novel drug combinations.
- Metastatic Disease Treatment
- Combination Therapy Approaches
- Dose Optimization Studies
- Novel Drug Development
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.